ARTICLE | Company News
Amira, GlaxoSmithKline deal
February 11, 2008 8:00 AM UTC
Amira granted GlaxoSmithKline exclusive, worldwide rights to develop, manufacture and commercialize 5-Lipoxygenase Activating Protein ( FLAP) inhibitors to treat respiratory and cardiovascular disease. Inhibiting FLAP in turn inhibits cysteinyl leukotriene receptor 1 (CysLT1), CysLT2 and leukotriene B4 type 1 receptor (BLT1) in the leukotriene pathway. ...